In a multicenter phase Ib clinical study involving 56 GIST patients resistant to imatinib and sunitinib, the PI3K inhibitor alpelisib combined with imatinib also failed due to lack of additional benefits and excessive adverse reactions [79]. This evidence concerns the gene PIK3CA and gastrointestinal stromal tumor.